1
|
Silvestri O, Accarino G, Turchino D, Squizzato F, Piazza M, Bastianon M, Di Gregorio S, Pratesi G, Antonello M, Costa D, Serra R, Bracale UM. Mid-Term Results of an Italian Multicentric Experience with the Roadsaver TM Dual-Layer Carotid Stent System. Healthcare (Basel) 2024; 12:120. [PMID: 38201025 PMCID: PMC10778716 DOI: 10.3390/healthcare12010120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2023] [Revised: 12/13/2023] [Accepted: 01/03/2024] [Indexed: 01/12/2024] Open
Abstract
BACKGROUND Carotid artery stenting (CAS) using first-generation single-layer stents is widely accepted as a good alternative to standard carotid endarterectomy (CEA) but it is associated with worse outcomes in terms of both plaque prolapse and cerebral embolization. AIM To evaluate the perioperative and midterm outcomes of CAS using the new-generation RoadsaverTM dual-layer micromesh-covered carotid stent. METHODS Herein, we present the results of an observational, retrospective, multicentric study on non-consecutive patients who underwent the CAS procedure between January 2017 and December 2022 at three Italian, high-volume vascular surgery centers. The inclusion criteria were the patients' eligibility for the CAS procedure in accordance with the current Italian guidelines, and the implantation of a Roadsaver stent. Both symptomatic and asymptomatic patients were included in the study. The patients requiring reintervention for carotid restenosis following CEA were also included. Perioperative data regarding procedural success was defined as the successful implantation of the device in the desired position, less than 30% residual stenosis, and the absence of intraoperative neurological complications. The primary outcome was any adverse cerebrovascular event such as stroke or transient ischemic attack (TIA) during the procedure and/or after discharge. The secondary outcomes were the need for further intervention, and all-cause death following procedure. RESULTS Three-hundred-fifty-three (353) patients were included in our study; the mean age was 74.3 years. A total of 5.9% of the patients were symptomatic on their operated side, while 7.3% had contralateral carotid occlusion. A cerebral embolic protection device (CPD) was employed in all patients. A total of 13.3% of the patients were operated on for restenosis after CEA Technical success was achieved in 96.9% of the cases with an intraoperative report of six TIAs (1.7%) and six ipsilateral strokes (1.7%). The mean hospital stay was 1.8 days. The thirty-day follow up showed one TIA and one more stroke. At the mean 35-month follow-up time, the primary outcome was present in six patients (1.7%), where four TIAs (1.1%) and two strokes (0.5%) were reported. Restenosis occurred in five patients (1.4%). Death for any cause was reported in 11 patients (3.1%). CONCLUSIONS As most recent, high-quality studies show, the CAS procedure with second-generation devices such as the Roadsaver stent is safe and effective in preventing carotid-related cerebrovascular events in both symptomatic and asymptomatic patients. The intraoperative and postoperative cerebrovascular complication rate in high volume centers is very low, ensuring confidence in its employment for the CAS procedure along with a CPD as a valid alternative to CEA.
Collapse
Affiliation(s)
- Olga Silvestri
- Department of Public Health, Vascular Surgery Unit, University Federico II of Naples, 80131 Naples, Italy; (O.S.); (G.A.); (U.M.B.)
| | - Giulio Accarino
- Department of Public Health, Vascular Surgery Unit, University Federico II of Naples, 80131 Naples, Italy; (O.S.); (G.A.); (U.M.B.)
- Department of Medicine, Surgery and Dentistry, University of Salerno, 84084 Fisciano, Italy
| | - Davide Turchino
- Department of Public Health, Vascular Surgery Unit, University Federico II of Naples, 80131 Naples, Italy; (O.S.); (G.A.); (U.M.B.)
| | - Francesco Squizzato
- Department of Cardiac, Thoracic and Vascular Sciences and Public Health, School of Medicine, Padua University Hospital, 35100 Padua, Italy; (F.S.); (M.P.); (M.A.)
| | - Michele Piazza
- Department of Cardiac, Thoracic and Vascular Sciences and Public Health, School of Medicine, Padua University Hospital, 35100 Padua, Italy; (F.S.); (M.P.); (M.A.)
| | - Martina Bastianon
- Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino, University of Genova, 16100 Genova, Italy; (M.B.); (S.D.G.); (G.P.)
| | - Sara Di Gregorio
- Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino, University of Genova, 16100 Genova, Italy; (M.B.); (S.D.G.); (G.P.)
| | - Giovanni Pratesi
- Vascular and Endovascular Surgery, IRCCS Ospedale Policlinico San Martino, University of Genova, 16100 Genova, Italy; (M.B.); (S.D.G.); (G.P.)
| | - Michele Antonello
- Department of Cardiac, Thoracic and Vascular Sciences and Public Health, School of Medicine, Padua University Hospital, 35100 Padua, Italy; (F.S.); (M.P.); (M.A.)
| | - Davide Costa
- Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy;
| | - Raffaele Serra
- Interuniversity Center of Phlebolymphology (CIFL), International Research and Educational Program in Clinical and Experimental Biotechnology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy;
| | - Umberto Marcello Bracale
- Department of Public Health, Vascular Surgery Unit, University Federico II of Naples, 80131 Naples, Italy; (O.S.); (G.A.); (U.M.B.)
| |
Collapse
|